Revenue: As of FY2026 Q2, the actual value is USD 163.5 M, beating the estimate of USD 131.23 M.

EPS: As of FY2026 Q2, the actual value is USD -0.01.

EBIT: As of FY2026 Q2, the actual value is USD -13.4 M.

Consolidated Financial Performance

OPKO Health, Inc. reported an operating loss of - $7.0 million for the second quarter of 2026, a significant improvement from an operating loss of - $60.0 million in the corresponding 2025 quarter. The net loss also substantially improved to - $8.4 million in the second quarter of 2026, compared to a net loss of - $148.4 million in the same period of 2025. For the six months ended June 30, 2026, the operating loss was - $58.0 million, an improvement from - $127.1 million in 2025, and the net loss was - $63.3 million compared to - $216.1 million in 2025.

Pharmaceutical Segment

Total costs and expenses for the Pharmaceutical segment were $88.2 million in the second quarter of 2026, compared with $84.4 million in 2025. The segment reported an operating income of $0.8 million in the second quarter of 2026, which included $18.5 million in depreciation and amortization expense, a significant improvement from an operating loss of - $28.7 million in the same period of 2025.

Diagnostics Segment

Total costs and expenses for the Diagnostics segment were $69.8 million in the second quarter of 2026, a decrease from $119.3 million in 2025, which had included $29.4 million related to sold oncology assets. The segment achieved an income from operations of $4.8 million in the second quarter of 2026, including $3.9 million of depreciation and amortization expense, an improvement from an operating loss of - $18.2 million in the same 2025 period. An earnout of $18.1 million related to the oncology asset sale was received, offsetting operating expenses.

Cash Position and Stock Repurchases

As of June 30, 2026, OPKO Health, Inc. held $314.4 million in cash, cash equivalents, marketable securities, and restricted cash. The company repurchased approximately $105.3 million of its common stock under a program authorized in July 2025, including $13.2 million in the second quarter of 2026, with about $94.7 million remaining authorized for future repurchases.

Operational Highlights

OPKO Health, Inc. made significant progress in its clinical pipeline, including ModeX presenting data on multispecific antibody targeted in vivo CAR T cell programs and initiating enrollment for the MDX2003 Phase 1 clinical trial. The company also started the MDX2301 Phase 1 clinical trial for COVID-19 prevention and continued Phase 1 enrollment for MDX2001 and MDX2004. Furthermore, OPKO initiated a Phase 1/2a clinical study for OPK-88006 and expanded its agreement with Nicoya, receiving a 15% equity stake and eligibility for up to $115 million in milestones.

Financial Guidance

For the third quarter of 2026, OPKO Health, Inc. anticipates total revenue between $131 million and $142 million, with total costs and expenses expected to range from $180 million to $190 million, including R&D expenses of $34 million to $38 million. For the full year 2026, the company forecasts total revenue of $560 million to $585 million. Full-year total costs and expenses are guided to be $710 million to $740 million, with R&D expenses between $125 million and $135 million.